Marker Therapeutics Stock In The News

MRKR Stock  USD 3.89  0.09  2.26%   
Our overall analysis of Marker Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Marker Therapeutics. The specific impact of Marker Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Marker Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Marker Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Marker Therapeutics Backtesting and Marker Therapeutics Hype Analysis.
To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.

Marker Therapeutics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
https://www.globenewswire.com/news-release/2023/11/09/2777937/0/en/Marker-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html
 Neutral
Macroaxis News: globenewswire.com
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
https://www.globenewswire.com/news-release/2023/09/11/2740646/0/en/Marker-Therapeutics-Announces-Complete-Response-in-First-Lymphoma-Patient-Treated-with-MT-601-after-CAR-T-Relapse.html
 Neutral
Macroaxis News: globenewswire.com
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
https://www.globenewswire.com/news-release/2023/08/30/2734294/0/en/Marker-Therapeutics-to-Present-at-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
https://www.globenewswire.com/news-release/2023/08/14/2725057/0/en/Marker-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html
 Bullish
Macroaxis News: globenewswire.com
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
https://www.globenewswire.com/news-release/2023/08/07/2719578/0/en/Marker-Therapeutics-Reports-Non-Clinical-Proof-of-Concept-Data-and-Update-on-Clinical-Readiness-for-the-MT-401-Off-the-Shelf-Program.html
 Neutral
Macroaxis News: globenewswire.com
Marker Therapeutics to Participate in Vi...
https://www.globenewswire.com/news-release/2023/07/26/2711174/0/en/Marker-Therapeutics-to-Participate-in-Virtual-Roundtable-with-Key-Opinion-Leaders-to-Discuss-Clinical-Landscape-of-CAR-T-Cell-Therapies-on-August-9-2023.html
 Neutral
Yahoo News
Marker Therapeutics to Participate in Vi...
https://finance.yahoo.com/news/marker-therapeutics-participate-virtual-roundtable-110000384.html
 Neutral
Yahoo News
Marker Therapeutics (NASDAQ:MRKR) hikes 26% this week, taking one-year gains to 95%
https://finance.yahoo.com/news/marker-therapeutics-nasdaq-mrkr-hikes-121249119.html
 Bullish
Macroaxis News: globenewswire.com
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
https://www.globenewswire.com/news-release/2023/07/10/2701638/0/en/European-Medicines-Agency-Grants-Orphan-Drug-Designation-for-MT-401-developed-by-Marker-Therapeutics-for-the-Treatment-of-AML-Patients.html
 Bullish
Yahoo News
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
https://finance.yahoo.com/news/european-medicines-agency-grants-orphan-110000787.html
 Bullish

Marker Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Marker and other traded companies coverage with news coverage. We help investors stay connected with Marker headlines for the 12th of December 2024 to make an informed investment decision based on correlating the impacts of news items on Marker Stock performance. Please note that trading solely based on the Marker Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Marker Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Marker Therapeutics investors visualize upcoming and past events in order to time the market based on Marker Therapeutics noise-free hype analysis.
Marker Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Marker earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Marker Therapeutics that are available to investors today. That information is available publicly through Marker media outlets and privately through word of mouth or via Marker internal channels. However, regardless of the origin, that massive amount of Marker data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Marker Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Marker Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Marker Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Marker Therapeutics alpha.

Marker Largest EPS Surprises

Earnings surprises can significantly impact Marker Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-07
2024-09-30-0.39-0.260.1333 
2021-08-10
2021-06-30-1.17-1.3-0.1311 
2024-08-14
2024-06-30-0.43-0.290.1432 
2021-05-12
2021-03-31-1.45-1.6-0.1510 
2020-03-12
2019-12-31-1.26-1.10.1612 
2022-08-11
2022-06-30-1.27-1.10.1713 
View All Earnings Estimates

Marker Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Marker Therapeutics Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
Gurufocus Stories at Macroaxis
10th of December 2024
Acquisition by Hoang Peter L. of 430000 shares of Marker Therapeutics at 3.06 subject to R...
at gurufocus.com 
bizjournals News
3rd of December 2024
Baylor College of Medicine-partnered Marker Therapeutics files for 11.4M offering
at bizjournals.com 
Google News at Macroaxis
22nd of November 2024
Marker Therapeutics gets 2M NIH grant for MT-601 Phase 1 study - MSN
at news.google.com 
Gurufocus Stories at Macroaxis
14th of November 2024
Marker Therapeutics Inc Q3 2024 Earnings EPS of -0.26, Revenue Surpasses Estimates at 1. ....
at gurufocus.com 
Simply Wall St News at Macroaxis
23rd of October 2024
US Penny Stocks To Consider In October 2024
at simplywall.st 
Google News at Macroaxis
30th of September 2024
Omega Therapeutics stock hits 52-week low at 1.2 - Investing.com
at news.google.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Marker Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Marker Therapeutics' short interest history, or implied volatility extrapolated from Marker Therapeutics options trading.

Additional Tools for Marker Stock Analysis

When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.